MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE AND COMPARE

非甾体抗炎药（NSAIDs）是处方最广泛的一类药物。虽然这类药物通常是安全的，但可能与严重的胃肠道和肾脏不良反应有关，其疗效和毒性都归因于对环加氧酶（COX）的抑制。环加氧酶最近被发现存在于COX-1和COX-2两种亚型中，COX-1参与维持前列腺素和COX-2参与炎症性前列腺素的产生。目前，可用的非甾体抗炎药（NSAIDs）已被定性为COX-1和COX-2双重抑制剂。这是一项双盲、安慰剂对照、多中心、双虚拟、平行组研究，旨在评估和比较多剂量选择性COX-2抑制剂MK-0966、吲哚美辛和安慰剂对65至80岁、肌酐清除率30至80 ml/分钟受试者肾功能的影响。

Nonsteroidal anti-inflammatory drugs (NSAIDs) are on of the most widely prescribed class of medications. While generally safe, this class of medications may be associated with serious gastrointestinal and renal adverse effects, both the efficacy and toxicity is attributed to the inhibition of cyclo-oxygenase (COX). Cyclo-oxygenase has recently been discovered to exist in two isoforms COX-1 which is involved in maintenance prostaglandins and COX-2 which is involved in the production of inflammatory prostaglandins. Currently, available nonsteroidal anti- inflammatory drugs (NSAIDs) have been characterized as dual COX-1 and COX-2 inhibitors. This is a double-blind, placebo-controlled, multicenter, double-dummy, parallel group study to evaluate and compare the effects of multiple doses of the selective COX-2 inhibitor MK-0966, indomethacin, and placebo on renal function in subjects 65 to 80 year of age with creatinine clearance 30 to 80 ml/minute.